|View printer-friendly version|
|November 30, 2011 10:58 p.m.|
|Teva Announces Agreement with Ranbaxy Regarding Generic Lipitor®|
Jerusalem, Israel, November 30, 2011 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy’s sales of Atorvastatin Calcium Tablets during Ranbaxy’s 180-day first-to-file exclusivity period, will be paid to Teva. Terms of the agreement will not be disclosed.
Atorvastatin Calcium Tablets are the generic version of Pfizer’s Lipitor® Tablets. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data.
Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: